for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fresenius Medical Care AG & Co. KGaA

FMEG.DE

Latest Trade

75.68EUR

Change

-1.90(-2.45%)

Volume

1,084,573

Today's Range

75.30

 - 

77.88

52 Week Range

57.24

 - 

81.10

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
77.58
Open
77.32
Volume
1,084,573
3M AVG Volume
16.29
Today's High
77.88
Today's Low
75.30
52 Week High
81.10
52 Week Low
57.24
Shares Out (MIL)
300.36
Market Cap (MIL)
23,039.78
Forward P/E
--
Dividend (Yield %)
1.59

Next Event

Fresenius Medical Care AG & Co KGaA at Morgan Stanley European MedTech & Services Conference

Latest Developments

More

Fresenius Medical Care Says Too Early To Quantify Potential Impact From Coronavirus To Asia-Pacific Operations

ChemoCentryx And VFMCRP Announce Positive Topline Data From Pivotal Phase III ADVOCATE Trial

FMC AG Says Internal Control Over Financial Reporting And Disclosure Controls And Procedures Were Not Effective At June 30, 2019 Due To Material Weakness

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

Contact Info

Else-Kroener-Strasse 1

+49.6172.6090

https://www.freseniusmedicalcare.com/

Executive Leadership

Dieter Schenk

Chairman of the Supervisory Board

Rice Powell

Chairman of the Management Board, Chief Executive Officer

Ben J. Lipps

Honorary Chairman

Rolf A. Classon

Independent Vice Chairman of the Supervisory Board

Helen Giza

Chief Financial Officer, Member of the Management Board

Key Stats

2.15 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

17.8K

2018

16.5K

2019

17.5K

2020(E)

18.5K
EPS (EUR)

2017

4.170

2018

4.490

2019

4.520

2020(E)

4.550
Price To Earnings (TTM)
19.07
Price To Sales (TTM)
1.32
Price To Book (MRQ)
1.72
Price To Cash Flow (TTM)
7.60
Total Debt To Equity (MRQ)
104.07
LT Debt To Equity (MRQ)
79.56
Return on Investment (TTM)
6.43
Return on Equity (TTM)
4.86

Latest News

Latest News

Fresenius forecasts 2020 profit growth driven by drug, dialysis units

German healthcare group Fresenius <FREG.DE> said it expects net income to increase in 2020 after strong growth in its dialysis business, and in its infusion drugs unit in emerging markets, helped it to just beat fourth quarter expectations.

FMC sees U.S. government easing home dialysis goals

Fresenius Medical Care (FMC) , the world's largest kidney dialysis provider, is confident the U.S. government will soften initial targets for treating patients with kidney disease at home rather than in dedicated centres.

Fresenius Medical says fourth-quarter operating profit up 3%

Germany's Fresenius Medical Care <FMEG.DE> on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America.

Fresenius Medical says Q4 operating profit up 3%

Germany's Fresenius Medical Care on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America.

Fresenius beats third-quarter forecasts with strong sales of home dialysis treatments

German healthcare group Fresenius <FREG.DE> beat third-quarter revenue forecasts on Tuesday, citing a solid performance by its infusion drugs unit in emerging markets and strong growth in home treatment at its separately listed dialysis business.

Fresenius Medical Care reports Q3 beat on record home dialysis in North America

German dialysis specialist Fresenius Medical Care reported on Tuesday a 9% rise in its third-quarter revenue, citing record growth in home dialysis in North America.

Fresenius Medical Care appoints Takeda executive Helen Giza as CFO

German dialysis specialist Fresenius Medical Care <FMEG.DE> has hired Helen Giza from Japan's Takeda Pharmaceutical <4502.T> as its new finance chief, replacing Mike Brosnan.

Fresenius slides as weakness in dialysis unit offsets improved outlook

Shares in German healthcare group Fresenius <FREG.DE> slid on Tuesday after its dialysis unit FMC reported smaller than expected cost savings and said full-year earnings growth would likely come in at the lower end of guidance.

Fresenius Medical Care confirms 2019 targets

German dialysis specialist Fresenius Medical Care <FMEG.DE> reported on Tuesday a 3% rise in its second-quarter revenue, citing healthy growth in its U.S. dialysis business.

Shareholders reproach Germany's Fresenius Medical Care after foreign bribery case

* ISS recommends no confidence vote on U.S. bribery settlement

Fresenius makes solid start to year after turbulent 2018

Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation.

Fresenius Medical Care to pay $231 million to resolve criminal, civil foreign bribery charges

Germany-based dialysis clinic operator Fresenius Medical Care AG will pay about $231 million to resolve criminal and civil allegations that the company paid bribes to public health and government officials in several countries to win or retain business, the U.S. Justice...

FMC wraps up $2 bln acquisition of NxStage

Germany's Fresenius Medical Care (FMC) wrapped up its $2 billion acquisition of U.S. home dialysis maker NxStage Medical on Friday, according to a U.S. Securities and Exchange Commission filing.

Fresenius flags faster earnings growth from 2020 after investment

Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday.

FMC expects NxStage deal to close in next couple of days

Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days.

RPT-Fresenius Medical Care plans 1 bln eur share buyback

Fresenius Medical Care, the world's biggest provider of dialysis services, signalled a return to profit growth from 2020 on Wednesday and said it would buy back shares worth 1 billion euros ($1.13 billion) over the next two years.

Fresenius Medical Care plans 1 bln eur share buyback

Fresenius Medical Care, the world's biggest provider of dialysis services, signalled a return to profit growth from 2020 on Wednesday and said it would buy back shares worth 1 billion euros ($1.13 billion) over the next two years.

Fresenius expects earnings to stagnate in 2019 as investments weigh

German healthcare group Fresenius said sales growth would slow and profit stagnate this year as investments to fix the performance at its German hospitals business and build up home dialysis take a toll.

U.S. approves Fresenius purchase of NxStage

The U.S. Federal Trade Commission has given Germany's Fresenius Medical Care AG and U.S. home dialysis equipment maker NxStage Medical Inc antitrust approval for their merger, the agency said on Tuesday.

US approves Fresenius purchase of NxStage with conditions

The U.S. Federal Trade Commission has given Fresenius Medical Care AG and NxStage Medical Inc antitrust approval for their merger with conditions, the agency said on Tuesday. (Reporting by Diane Bartz Editing by James Dalgleish)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up